English Abstract
Journal Article
Add like
Add dislike
Add to saved papers

[Significance of alloantibodies other than anti-D hemolytic disease of the fetus and newborn (HDF/N)].

Ginekologia Polska 2003 January
OBJECTIVE: Because of immunoprophylaxis, the proportion between HDF/N caused by anti-D and other antibodies have changed. We assessed HDF/N due to non anti-D among women with antibodies detected during a screening programme.

MATERIAL AND METHODS: Blood samples from 507 women with antibodies were examined for Ig class of antibody, specificity, the titer by routine serological tests and for functional activity by chemilumine-scence test (CLT). The father's and fetal/newborn's blood was also examined.

RESULTS: Among 507 women, anti-D was detected in 231 (45.5%), non-anti-D (potentially clinically important) in 106 (21%), and in 170 (33.5%) IgM of various specificity regarded as clinically benign. The first and last group will not be discussed. Among 106 cases with non anti-D in 46 (43%) antibodies reacted with antigens from Rh system (C,c,E,e,G,Rh17), in 35 (33%) with K and k (only 1), and in 25 (24%) with other antigens. Feto-maternal incompatibility was found in 50 cases. HDF/N was diagnosed as: mild (without treatment) in 27 (54%) cases, moderate (phototerapy and/or top-transfusions) in 12 (24%), severe (exchange transfusions) in 4 (8%) and very severe (intrauterine transfusions, oedema and death) in 7 (14%) cases.

CONCLUSIONS: Among 337 women with clinically significant antibodies, in 106 cases, they reacted with a non-D antigen. 37% of mothers had children with HDF/N, including two rare cases due to anti-Rh17 and anti-G. Most had mild/moderate HDF/N, however 22% severe/very severe due to anti-c, -E, -K, two of them died in utero. The CLT results were helpful in prognosing the severity of HDF/N.

Full text links

We have located links that may give you full text access.
Can't access the paper?
Try logging in through your university/institutional subscription. For a smoother one-click institutional access experience, please use our mobile app.

Related Resources

For the best experience, use the Read mobile app

Mobile app image

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app

All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.

By using this service, you agree to our terms of use and privacy policy.

Your Privacy Choices Toggle icon

You can now claim free CME credits for this literature searchClaim now

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app